2 files

Early Itch Response with Abrocitinib is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE 3 COMPARE Trial

posted on 22.11.2022, 18:12 authored by Adis Journals on behalf of:, Sonja Ständer, Shawn G. Kwatra, Jonathan I. Silverberg, Eric L. Simpson, Jacob P. Thyssen, Gil Yosipovitch, Fan Zhang, Michael C. Cameron, Ricardo Rojo Cella, Hernan Valdez, Marco DiBonaventura, Claire Feeney

Article full text

The above features represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite). 

© The authors, CC-BY-NC 2022